Incidence of Cereblon in Intensive Care Patients

计划入组 30 人 · 首次发布于 2021 年 10 月 19 日

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

计划入组 135 人 · 首次发布于 2025 年 3 月 26 日

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

计划入组 24 人 · 首次发布于 2026 年 1 月 21 日

CRBN(FLT3)-8

Homo-PROTAC cereblon degrader 1

CRBN-6-5-5-VHL

CEREBOS PACIFIC LIMITED

Singapore

Sichuan Crun Co.,Ltd

China

Kangpu's Novel Cereblon Modulator Shows 50% Response Rate in Heavily Pre-treated Multiple Myeloma Patients

ADAR1 Gene Identified as Key Driver of Lenalidomide Resistance in Multiple Myeloma

The Second Act of Thalidomide: From Teratogen to the Foundation of Targeted Protein Degradation